Welcome! As the Novartis team in Brussels, we represent our company on European level and operate as the connecting piece between corporate, EU and trade associations.
Learn more about our priorities, how we reimagine medicine, get to know our team and stay in touch with us on Twitter: @NovartisEU!
In 2022, we continued to reimagine medicine and deliver on our purpose to improve and extend people’s lives.
To reimagine medicine is our overarching goal, therefore we’re focusing on access, digitization, ESG, the pharma review, rare disease and security of supply.
We are committed to work with all stakeholders to develop collaborative and sustainable access solutions that address affordability concerns but more important, ensuring that patients have the right access to the right treatment.
We have embarked on an ambitious transformation to become the leading medicines company powered by data science and digital technologies. New technologies have the potential to improve applications that will improve patients’ lives.
Very ambitious targets are launched to be a leader in environmental sustainability in the healthcare industry, further strengthening its already ambitious target for carbon neutrality to include its entire supply chain by 2030.
The General Pharmaceutical Legislation is a once-in-a-generation opportunity to refine and evolve Europe’s regulatory framework – for a better future for patients and industry.
Our mission is to reimagine medicine to improve and extend people’s lives, including transformative medicines for rare disease patients and children in Europe and around the world.
Working closely with competent authorities to ensure all patients have timely access to high quality treatments and medicines. In order to achieve this policy priorities should be on security of supply, rather than on localization of manufacturing.
Stands for European Federation of Pharmaceutical Industries and Associations representing biopharmaceutical industry operating in Europe. EFPIA has a direct membership of 36 national associations and 39 leading pharmaceutical companies.
Is Europe's trade body for innovative companies working in the field of pharmaceuticals and medical technologies who are active in research, development of pharmaceuticals, biotechnologies and medical devices.
The European Association for Bioindustries, promotes an innovative and dynamic European biotechnology industry. They represent 78 corporate, associate members and bioregions & 15 national biotechnology associations representing over 1800 biotech SMEs.
Represents the European generic, biosimilar and valued added pharmaceutical industries. Their members’ portfolio covers 80% of therapy areas, and in so doing, safeguards the sustainability of Europe’s healthcare systems for future generations.
